Headlines | May 29th

Psychedelic Finance Weekly Headlines direct to your email inbox: Subscribe Now

Markets

Market performance of publicly-listed psychedelic companies for the week of May 25th - 29th.

‍

Deals/Updates

‍

Champignon Brands ($SHRM | $SHRMF | $496) appointed Dr. Bill Wilkerson, award-winning pioneer in workplace mental health, to its board of directors. Press Release. The company also announced an extended share lock-up restricting the resale of 17,840,000 common shares. Press Release

‍

MindMed ($MMED | $MMEDF) officially closed its upsized bought deal short form prospectus offering for gross proceeds of C$13,225,540. Press Release. MindMed also announced that it has expanded its collaboration with UHB's Liechti Lab, adding MDMA to its R&D pipeline and gaining access to a compelling portfolio of clinicaltrials and studies gathered by the Liechti Lab over a 10 year period. Press Release

‍

Numinus ($NUMI) added physician and bestselling author Dr. Gabor Maté to it's Clinical Advisory Council (Press Release) and released their 2020 operational plans to scale. Press Release

‍

New Wave Holdings Corp ($SPOR | $TRMNF | $0XM2) announced a sponsorship of TheraPsil, a BC-based non-profit coalition that is seeking legal access to psilocybin for Canadians with a palliative diagnosis and psychological distress. Press Release

‍

Field Trip Psychedelics Inc (Private) announced a private placement, seeking to raise US$20,000,000 at a pre-money value range of US$65,000,000 - US$75,000,000. Interview with CEO, Ronan Levy

‍

Media

‍

VICE Magazine: Get Ready for Pharmaceutical Grade Magic Mushroom Pills, by Shayla Love

‍

Champignon Brands ($SHRM | $SHRMF | $496) released a new video with CEO Dr. Roger McIntrye. Video Link. The company was also featured in Business Insider.

‍

Psychedelic Science Review covered the crystal structure of MPT, a structural analog of DMT. Link

‍